|本期目录/Table of Contents|

[1]张 昕,张洁利,李小溪,等.疟疾药物预防的现状与进展[J].传染病信息,2019,05:445-450.
 ZHANG Xin,ZHANG Jie-li,LI Xiao-xi,et al.Status and progress of chemoprophylaxis for malaria[J].Infectious Disease Information,2019,05:445-450.
点击复制

疟疾药物预防的现状与进展(PDF)

《传染病信息》[ISSN:1007-8134/CN:11-3886/R]

期数:
2019年05期
页码:
445-450
栏目:
综述
出版日期:
2019-11-13

文章信息/Info

Title:
Status and progress of chemoprophylaxis for malaria
文章编号:
1007-8134(2019)05-0445-07
作者:
张 昕张洁利李小溪陈典洁黄 磊
100039北京,中国人民解放军总医院第五医学中心 感染性疾病诊疗与研究中心(张昕、张洁利、陈典洁、黄磊), 临床检验医学中心(李小溪) 前两位作者对本文有同等贡献,均为第一作者
Author(s):
ZHANG Xin ZHANG Jie-li LI Xiao-xi CHEN Dian-jie HUANG Lei*
Center for Infectious Disease Diagnosis and Treatment, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China ZHANG Xin and ZHANG Jie-li are the first authors who contributed equally to the article
关键词:
疟疾预防抗疟药物
Keywords:
malaria chemoprophylaxis antimalarial
分类号:
R531.3
DOI:
10.3969/j.issn.1007-8134.2019.05.017
文献标识码:
A
摘要:
近年来,疟疾的发病率已明显下降,但仍然是全球最重要的公共卫生负担。目前预防用药可以大大降低其发病率、病死率,控制传播,但长时间服药带来的不良反应及耐药等问题亟待解决,新的药物或组合方案应具有良好的耐受性、安全性和有效性。本文就疟疾预防用药的现状及进展作一综述。
Abstract:
Despite obviously declining incidence, malaria continues to be the most significant public health burdenglobally. At present, prophylactic agents are used to decrease the morbidity and mortality, and control the transmission. However, adverse effects caused by a prolonged treatment course and drug resistance make it imperative to look for alternative drugs orcombining scheme with a better tolerability, safety and efficacy. This review summarizes current situation and new approach of chemoprophylaxis for malaria.

参考文献/References

[1] World Health Organization. From 30 million to zero: China creates a malaria-free future2019[EB/OL].[2019-07-15]. https:// www.who.int/news-room/feature-stories/detail/from-30-millionto- zero-china-creates-a-malaria-free-future.
[2] United Nation Mission in Liberia. Unmil focus[M]. Accra Ghana: Buck Press Ltd:30-32.
[3] Wangdi K, Furuya-Kanamori L, Clark J, et al. Comparative effectiveness of malaria prevention measures: a systematic review and network meta-analysis[J]. Parasit Vectors, 2018, 11(1):210.
[4] Camarda G, Jirawatcharadech P, Priestley RS, et al. Antimalarial activity of primaquine operates via a two-step biochemical relay[J]. Nat Commun, 2019, 10(1):3226.
[5] Untaroiu AM, Carey MA, Guler JL, et al. Leveraging the effects of chloroquine on resistant malaria parasites for combination therapies [J]. BMC Bioinformatics, 2019, 20(1):186.
[6] Warsame M, Hassan AM, Hassan AH, et al. High therapeutic efficacy of artemether-lumefantrine and dihydroartemisininpiperaquine for the treatment of uncomplicated falciparum malaria in Somalia[J]. Malar J, 2019, 18(1):231.
[7] Guidi M, Mercier T, Aouri M, et al. Population pharmacokinetics and pharmacodynamics of the artesunate-mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children[J]. Malar J, 2019, 18(1):139.
[8] Yang H, Wang J, Liu H, et al. Randomized, double-blind, placebocontrolled studies to assess safety and prophylactic efficacy of naphthoquine-azithromycin combination for malaria prophylaxis in Southeast Asia[J]. Antimicrob Agents Chemother, 2018, 62(9):pii:taw064.
[9] Lachish T, Bar-Meir M, Eisenberg N, et al. Effectiveness of twice a week prophylaxis with atovaquone-proguanil (Malarone?) in long-term travellers to West Africa[J]. J Travel Med, 2016, 23(6):pii:taw064.
[10] Heppner DG Jr, Walsh DS, Uthaimongkol N, et al. Randomized, controlled, double-blind trial of daily oral azithromycin in adults for the prophylaxis of Plasmodium vivax malaria in Western Thailand[J]. Am J Trop Med Hyg, 2005, 73(5):842-849.
[11] Andersen SL, Oloo AJ, Gordon DM, et al. Successful doubleblinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya[J]. Clin Infect Dis, 1998, 26(1):146-150.
[12] Taylor WR, Richie TL, Fryauff DJ, et al. Tolerability of azithromycin as malaria prophylaxis in adults in Northeast Papua, Indonesia[J]. Antimicrob Agents Chemother, 2003, 47(7):2199-2203.
[13] Ashley EA, Dhorda M, Fairhurst RM, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria[J]. N Engl J Med, 2014, 371(5):411-423.
[14] World Health Organization. World malaria report 2018[EB/OL]. [2019-07-15]. https://www.who.int/malaria/publications/worldmalaria- report-2018/en/.
[15] Gutman J, Kovacs S, Dorsey G, et al. Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and metaanalysis [J]. Lancet Infect Dis, 2017, 17(2):184-193.
[16] Olaleye A, Okusanya BO, Oduwole O, et al. A systematic review and meta-analysis of dihydroartemisinin-piperaquine versus sulphadoxine-pyrimethamine for malaria prevention in pregnancy [J]. Int J Gynaecol Obstet, 2019, 146(1):43-55.
[17] Kakuru A, Jagannathan P, Muhindo MK, et al. Dihydroartemisininpiperaquine for the prevention of malaria in pregnancy[J]. N Engl J Med, 2016, 374(10):928-939.
[18] Kayentao K, Garner P, van Eijk AM, et al. Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in Africa: systematic review and meta-analysis[J]. JAMA, 2013, 309(6):594-604.
[19] Andrejko KL, Mayer RC, Kovacs S, et al. The safety of atovaquoneproguanil for the prevention and treatment of malaria in pregnancy: a systematic review[J]. Travel Med Infect Dis, 2019, 27:20-26.
[20] World Health Organization. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults, 2006[EB/OL].[2019-07-15]. https://www. aidsdatahub.org/sites/default/files/documents/WHO2006_ Guidelines_for_Cotrimoxazole_Prophylaxis_for_HIV_in_ Resource_Limited_Settings_Recommendations_for_Public_Health.pdf.pdf.
[21] Denoeud-Ndam L, Zannou DM, Fourcade C, et al. Cotrimoxazole prophylaxis versus mefloquine intermittent preventive treatment to prevent malaria in HIV-infected pregnant women: two randomized controlled trials[J]. J Acquir Immune Defic Syndr, 2014, 65(2):198-206.
[22] Natureeba P, Kakuru A, Muhindo M, et al. Intermittent preventive treatment with dihydroartemisinin-piperaquine for the prevention of malaria among HIV-infected pregnant women[J]. J Infect Dis, 2017, 216(1):29-35.
[23] Saadani Hassani A, Marston BJ. Impact of cotrimoxazole and insecticide-treated nets for malaria prevention on key outcomes among HIV-infected adults in low- and middle-income countries: a systematic review[J]. J Acquir Immune Defic Syndr, 2015, 68(Suppl 3):S306-S317.
[24] Meremikwu MM, Donegan S, Sinclair D, et al. Intermittent preventive treatment for malaria in children living in areas with seasonal transmission[J]. Cochrane Database Syst Rev, 2012, (2):CD003756.
[25] World Health Organization. World malaria report[M]. Geneva: WHO, 2018.
[26] Aponte JJ, Schellenberg D, Egan A, et al. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials[J]. Lancet, 2009, 374(9700):1533-1542.
[27] Johnson BA, Kalra MG. Prevention of malaria in travelers[J]. Am Fam Physician, 2012, 85(10):973-977.
[28] Provost S, Gagnon S, Lonergan G, et al. Hepatitis A, typhoid and malaria among travelers--surveillance data from Québec (Canada) [J]. J Travel Med, 2006, 13(4):219-226.
[29] Stoney RJ, Chen LH, Jentes ES, et al. Malaria prevention strategies: adherence among Boston area travelers visiting malaria-endemic countries[J]. Am J Trop Med Hyg, 2016, 94(1):136-142.
[30] Massad E, Behrens BC, Coutinho FA, et al. Cost risk benefit analysis to support chemoprophylaxis policy for travellers to malaria endemic countries[J]. Malar J, 2011, 10:130.
[31] Shellvarajah M, Hatz C, Schlagenhauf P. Malaria prevention recommendations for risk groups visiting sub-Saharan Africa: a survey of European expert opinion and international recommendations[J]. Travel Med Infect Dis, 2017, 19:49-55.
[32] CDC. Choosing a drug to prevent malaria, 2018[EB/OL].[2019- 07-15]. https://www.cdc.gov/malaria/travelers/drugs.html.
[33] Boubaker R, Hérard Fossati A, Meige P, et al. Malaria prevention strategies and recommendations, from chemoprophylaxis to standby emergency treatment: a 10-year prospective study in a Swiss Travel Clinic[J]. J Travel Med, 2017, 24(5).
[34] H?gh B, Clarke PD, Camus D, et al. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team[J]. Lancet, 2000, 356(9245):1888-1894.
[35] 中华人民共和国国家卫生和计划生育委员会. WS/T485-2016 抗疟药使用规范[S]. 北京:卫生出版社,2016.
[36] 饶本强,丁燕,肖海. 赴利比里亚维和分队4 种疟疾预防方 案及效果比较[J]. 东南国防医药,2005,7(6):410-412.
[37] 王君平,李伟勇. 赴利比里亚维和部队应用抗疟片三号预防疟 疾的效果观察[J]. 热带病与寄生虫学,2007,5(3):171-172.
[38] 彭东长,陈琳,唐翔宇,等. 赴利比里亚维和医疗分队预防 疟疾的做法[J]. 华北国防医药,2010,22(4):110-111.
[39] 付留杰,朱涛,倪志杨,等. 南苏丹维和部队疟疾药物预防 及综合防制效果分析[J]. 医学动物防制,2013,29(5):493- 495,499.
[40] 彭程,高宏富,贾瑞忠,等. 维和部队药物与理化措施预防疟 疾效果观察[J]. 解放军预防医学杂志,2013,31(1):50-51.
[41] 凌磊,张绍维,叶晓卉,等. 中国首支赴刚果(金)维和医 疗分队疟疾发病情况及防护措施效果评价[J]. 解放军医学杂志,2004,29(10):915-916.
[42] 王秋生,王传力,房树志,等. 利比里亚任务区维和官兵的疟 疾预防措施的研究[J]. 现代预防医学,2011,38(3):550-551.
[43] Peragallo MS, Sarnicola G, Boccolini D, et al. Risk assessment and prevention of malaria among Italian troops in Afghanistan, 2002 to 2011[J]. J Travel Med, 2014, 21(1):24-32.
[44] DeJulio PA. You’re the flight surgeon. Malaria prevention in U.S. Air Force aviators[J]. Aerosp Med Hum Perform, 2016, 87(4):429-432.
[45] Gary WB, Jeffrey BN. CDC Yellow Book 2020. Health information for international travel[M]. Oxford: Oxford University Press, 2019.
[46] World Health Organization. Malaria, including proposal for establishment of world malaria dayannexes[EB/OL].[2019- 07-15]. http://apps.who.int/gb/ebwha/pdf_files/WHASSA_ WHA60-Rec1/E/reso-60-en.pdf?ua=1#page=32.
[47] Son DH, Thuy-Nhien N, von Seidlein L, et al. The prevalence, incidence and prevention of Plasmodium falciparum infections in forest rangers in Bu Gia Map National Park, Binh Phuoc Province, Vietnam: a pilot study[J]. Malar J, 2017, 16(1):444.
[48] Mutabingwa TK, Muze K, Ord R, et al. Randomized trial of artesunate+amodiaquine, sulfadoxine-pyrimethamine+amodiaquine, chlorproguanal-dapsone and SP for malaria in pregnancy in Tanzania [J]. PLoS One, 2009, 4(4):e5138.
[49] Rogerson SJ, Unger HW. Prevention and control of malaria in pregnancy - new threats, new opportunities?[J]. Expert Rev Anti Infect Ther, 2017, 15(4):361-375.
[50] Schlagenhauf P, Petersen E. Malaria chemoprophylaxis: strategies for risk groups[J]. Clin Microbiol Rev, 2008, 21(3):466-472.
[51] Oladimeji KE, Tsoka-Gwegweni JM, Ojewole E, et al. Knowledge of malaria prevention among pregnant women and non-pregnant mothers of children aged under 5 years in Ibadan, South West Nigeria[J]. Malar J, 2019, 18(1):92.
[52] Mayence A, Vanden Eynde JJ. Tafenoquine: a 2018 novel FDAapproved prodrug for the radical cure of Plasmodium vivax malaria and prophylaxis of malaria[J]. Pharmaceuticals (Basel), 2019, 12(3):pii:e115.
[53] Hale BR, Owusu-Agyei S, Fryauff DJ, et al. A randomized, doubleblind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum[J]. Clin Infect Dis, 2003, 36(5):541-549.
[54] Lell B, Faucher JF, Missinou MA, et al. Malaria chemoprophylaxis with tafenoquine: a randomised study[J]. Lancet, 2000, 355(9220):2041-2045.
[55] Walsh DS, Eamsila C, Sasiprapha T, et al. Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrugresistant P. falciparum malaria[J]. J Infect Dis, 2004, 190(8):1456-1463.
[56] Quinn JC, McCarthy S. Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria[J]. N Engl J Med, 2019, 380(19):1875.
[57] Tafenoquine succinate for malaria prevention[J]. Aust Prescr, 2019, 42(3):110-111.
[58] Phillips MA, White KL, Kokkonda S, et al. A Triazolopyrimidinebased dihydroorotate dehydrogenase inhibitor with improved druglike properties for treatment and prevention of malaria[J]. ACS Infect Dis, 2016, 2(12):945-957.
[59] Wu B, Du Y, Feng Y, et al. Oral administration of vitamin D and importance in prevention of cerebral malaria[J]. Int Immunopharmacol, 2018, 64:356-363.
[60] Dicko A, Roh ME, Diawara H, et al. Efficacy and safety of primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind, randomised controlled trial[J]. Lancet Infect Dis, 2018, 18(6):627-639.

备注/Memo

备注/Memo:
[基金项目]国家自然科学基金面上项目(81772185)
[作者单位]100039北京,中国人民解放军总医院第五医学中心 感染性疾病诊疗与研究中心(张昕、张洁利、陈典洁、黄磊), 临床检验医学中心(李小溪) 前两位作者对本文有同等贡献,均为第一作者
[通信作者]黄磊,E-mail:huangleiwa@sina.com
*Correspondingauthor,E-mail:huangleiwa@sina.com
更新日期/Last Update: 2019-11-13